|Bid||0.8100 x 800|
|Ask||0.8700 x 1100|
|Day's Range||0.8500 - 0.8800|
|52 Week Range||0.6000 - 2.3000|
|Beta (3Y Monthly)||2.16|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Seattle-based company said it had a loss of 19 cents per share. The biotechnology company posted revenue of $640,000 in the period. In the final minutes of trading on Thursday, the company's shares ...
On a per-share basis, the Seattle-based company said it had profit of 1 cent. The biotechnology company posted revenue of $14.1 million in the period. For the year, the company reported that its loss narrowed ...
The compensation hike comes at a time when CTI is cutting staff and subleasing extra office space in a bid to salvage its pipeline of cancer drug candidates.
The injection of funds comes at a critical time for CTI, which cut about half of its workforce in December as part of a restructuring plan.
Dr. James Bianco has faced multiple debt collection and class action lawsuits since stepping down as CEO of CTI BioPharma in late 2016.
It's one of two cancer drug startups that Dr. James Bianco has been linked to since leaving CTI BioPharma more than two years ago.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 13) Kezar Life Sciences Inc (NASDAQ: KZR ) Down In The Dumps ...
It’s CTI's latest attempt to salvage its pipeline of cancer drug candidates and reinvent the Seattle-based biotech after its co-founder and longtime CEO Dr. James Bianco stepped down in late 2016.
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -30.00% and 20.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Seattle-based company said it had a loss of 26 cents. The biotechnology company posted revenue of $723,000 in the period. The company's shares closed at $1.71. A year ago, they ...